Benefitting the Public with Technological Innovation
With technological innovation, methylation signals are recognized worldwide as the most accurate early cancer screening signals. Grail, a leading American company in the field of early cancer screening, uses the NGS platform to achieve this goal, but its high price discourages many people from using their tests.
Today, our company has successfully achieved the same accurate detection effect, but based on the Nobel Prize-winning PCR technology, and integrated our own innovative patented technology; at only 3% of the price of Grail. This breakthrough technology aims to enable Chinese consumers to enjoy the same level of medical testing services as in the United States, so that more people have the opportunity to enjoy the health protection brought by cutting-edge medical technology.
In the field of health technology, HymonBio has demonstrated its innovative strength again after 9 years. It will launch the world’s first PCR-based pan-cancer screening test kit, which can detect up to 28 high-incidence cancers using only one tube of blood. Not only that, its detection performance is almost on par with the world’s top products, with the negative predictive value is as high as 98.07%!
(P.S.: The higher the negative predictive value, the higher the credibility of the negative result, which is crucial for excluding diseases in physical examinations.)
Non-Invasive Testing for an Upgraded User Experience
HymonBio’s Pan-Cancer Screening Test Kit uses 5ml of non-invasive blood sample, making it simple and convenient, which greatly improves the patient’s compliance. Whether as a powerful tool for clinical auxiliary diagnosis or as a reliable means of health management, it provides users with more peace of mind.
HymonBio Opens Up a New Path
In today’s pan-cancer detection field, most companies rely on high-cost NGS technology to ensure accurate cancer detection, but HymonBio has chosen another innovative path. Based on the PCR technology platform that won the Nobel Prize in Chemistry in 1993, they superimposed their own innovative technology and combined it with the latest artificial intelligence analysis methods, pushing this traditional technology to a new height, with various performance indicators reaching the level of NGS.
Adapting to Local Conditions and Promoting Widespread Application
With the popularization of PCR instruments in China, HymonBio’s Pan-Cancer Screening Test Kit will be widely used in almost all medical institutions, including grassroots county hospitals, and become the pan-cancer screening program that is closest to the people.
Post time: Aug-18-2024